Navigation Links
Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
Date:2/1/2008

Robin R. Young to Provide 10-Year Forecast at 3rd Annual Stem Cell Summit

on Feb. 26

PHILADELPHIA, Feb. 1 /PRNewswire/ -- Stem cell product sales in the United States totaled $36 million in 2007, a 119 percent increase from the previous year, and are expected to reach $87 million, a 144 percent increase, in 2008, according to Robin R. Young, CFA, a medical industry analyst ranked as one of The Wall Street Journal's "Best on the Street" and among Institutional Investor's top-10.

The projections are based on Young's analysis of adult and human embryonic stem cell products currently sold or in development for the orthopedics, cardiovascular, anti-inflammatory, diabetes, nerve repair and dental markets.

"In recent months we've seen the largest stem cell product purchases in this fast-growing industry," Young said. "Physicians have already treated several thousands of patients in the United States with stem cell products. Moreover, the results of the clinical trials involving these types of products have been very impressive. This is a transformational year with the first-ever human embryonic stem cell products expected to enter the clinic."

Young will provide additional market data at the 3rd Annual Stem Cell Summit, which will take place Feb. 26 in New York City. The meeting is slated to be the largest gathering of stem cell company executives, scientists, investors and physicians. Attendees will learn about the investment opportunities in the stem cell marketplace, the groundbreaking stem cell products physicians are using today, and the growing market potential in terms of revenues. More information, including attendee registration details, is available at http://www.stemcellsummit.com.

Young has more than 25 years of experience as an analyst. He is the president of RRY Publications and the organizer of the Stem Cell Summit.

Contacts: Wendy Lau

Russo Partners, LLC

212-845-4272

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE RRY Publications
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
2. Mark Ostrowski Joins GenVault as Vice President of Sales and Marketing
3. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
4. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
5. /CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
8. ForceLogix, Innovex Win Sales Operational Performance Award
9. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... DIEGO , Dec. 8, 2016  Renova™ ... for congestive heart failure and type 2 diabetes, ... for a novel adeno-associated virus (AAV) vector developed ... , M.D., Ph.D., at Stanford University. The company ... its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review ... biotech crops. The authors focus on the economic effects in countries that are major ... new biotech crops and the resultant risk of low level presence (LLP) puts large ...
(Date:12/8/2016)... SEOUL, South Korea , Dec. 8, 2016 /PRNewswire/ ... completed a $21 billion KRW (US $18.9M) Series A ... Management, Kolon Investment, G.N. Tech Venture and SNU Bio ... by Eutilex to 30.5 billion KRW (US $27.7M) since ... will help Eutilex to bolster the development and commercialization ...
Breaking Biology Technology:
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/5/2016)... Dec. 5, 2016  The Office of Justice ... "Can CT Scans Enhance or Replace Medico Legal ... of supporting or replacing forensic autopsies with postmortem ... In response to recommendations made by ... using CT scans as a potential component of ...
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
Breaking Biology News(10 mins):